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Q-Probes study of Replicate Specimens at the Clinical
Laboratory, The Aga Khan University Hospital, Karachi
L. Ali,I. Siddiqui ( Section of Chemical Pathology, Department of Pathology, The Aga Khan University
Hospital, Karachi. )

Abstract
Objective: The aim of this Q-probes study was to evaluate the precision of replicate
specimens.
Methods: This Q-probes study done at the Clinical Laboratory, The Aga Khan
University Hospital Karachi is about routine chemistry analytes because of their
importance in critical care patients. The analytes data was collected for six months from
April to September 2002.There were total 358 samples, which were given for reanalysis
during this period under the constant working conditions. After analysis, results of both
the runs on different days, were compared to determine the percent difference between
the results. After calculating the percent difference, the results were either accepted or
rejected on the basis of guidelines set by CLIA 88(Clinical Laboratories Improvement
Amendment 1988).
Results: Among 358 results, 5 were rejected according to the criteria selected. All of
these results were then subjected to statistical analysis for calculating statistical
significance. As our Null hypothesis was that the prevalence of rejected results were
more than 2% with an acceptable limit of less than or equal to 2%. We failed to accept
the Null hypothesis that means that it did not exceed the acceptable limits (p-value=
0.962930) with the Confidence Interval range of 0.2 -2.6 where Upper Confidence
Interval is still less than 5% for a p-value of 0.05. The rejection of null hypothesis favors
high precision between the two sets of results in our studied population.
Conclusion: It is concluded that Q-Probes study of replicate specimens at the Clinical
Laboratory at The Aga Khan University Hospital is within the acceptable limits. These
figures show that a high quality precision is maintained among the observed specimens.
This is an ongoing exercise and studies like these should be a continuous process to
maintain and enhance the quality of Laboratory results (JPMA 54:52;2004).
Introduction
The explosion in technology is providing the clinical laboratory professionals a renewed
chance to become a productive member of health care providers and changing the
concepts regarding chemical pathologist, even in Pakistan. 1 The quality of clinical
laboratory testing is important and laboratory replicate sample analysis is used to
determine reproducibility or consistency in methods. 2 This Q-probes study has been
designed to evaluate precision of replicate specimens as measured by the percent
difference of previous day results. Replicate sample analysis is used to determine
reproducibility or consistency in methods. Precision has been examined through the
repetitive analysis of a series of blind QC materials. 3 Efforts to improve the quality of
laboratory testing have been impressive with the variability of analytical performance. It
is now less than one twentieth of what it was more than 40 years ago.4 Recent regulatory

and accrediting guidelines now require that, laboratory physicians begin to change their
improvement efforts from analytical step to other steps of total testing processes. 5-7 Qprobes, a quality improvement program of The college of American Pathologist (CAP),
which has provided almost 100 studies for large numbers of participants in Pathology and
laboratory medicine between 1989 and 1999.8
Material and Methods
This is a prospective study with the approach enhance quality of laboratory results to
improve patient care. The approach was deployed to identify problems, develop
corrective interventions and to evaluate their effectiveness in further studies. This method
of quality control focuses on replicate specimen analysis perform on routine basis for
monitoring
and
improving
performance.
Our laboratory technologists maintain a record daily replicate specimen analysis. This Qprobes study about routine chemistry analytes because of their importance in critical care
patients. The parameters included in our replicate study were blood urea nitrogen
creatinine, glucose, sodium and potassium. Regarding specimen storage policy, we used
follow recommended protocols, i.e., tubes containing se are closed at all times except at
the time of analysis. These tubes are kept in the vertical stopper up position. The se is
physically separated from contact with cells as soon possible. After separating the serum,
we refrigerate them seven days and this is the policy for all the specimens included in our
replicate study. We have done the study our section in which we have looked that these
specimens can be refrigerated for a long time and even the glucose sample can be put at
the room temperature for two days without any effect on results. The laboratory physician
randomly selects specimens from previous day, checks the record of results issued to
patients. After obtaining the results from previous day, the Laboratory physician assigns
the same sample for analysis (with the same analytes to measure) to the slime bench with
anonymous labeling to avoid any bias. This specimen is re-run for the same analytes
under similar conditions. The bench technologists are unaware of the previous day
results. After analysis, results of both the runs on different days are compared to
determine the percentage difference between the results. The analyte data was collected
for 6 months from April -September 2002. There was a total of 358 samples analytes that
were given for re-analysis during this period. On an average 3 specimens were given for
individual analysis each day during the official working days. % Difference was
calculated for each pair of results. (% Difference of sample = x-y/z ' 100; where x is
result of pervious day, y is re-run result and z = x+y/2). After calculating the %
difference, the results were either accepted or rejected on the basis of guidelines set by
CLIA, 1988 (Clinical Laboratories Improvement Amendment 1988). Every year, CLIA
1988 guidelines are revised by the center of Disease Control and Prevention which are
published in Federal register like for example this year they have added HIPPA
compliance Act in 2002.9
Results
Among 358 results, 5 were rejected according to the criteria selected. The results rejected
included I Potassium, 2 Sodium and 2 Creatinine. All of these were then subjected to

statistical analysis for calculating significance. As our Null hypothesis was that the
prevalence for the proportion of rejected results was more than 2%. (An acceptable limit
is less then or equal to 2%). We fail to accept the Null hypothesis that means that it did
not exceed the acceptable limit (p-value = 0.962930) with the Confidence Interval range
of 0.2 -2.6 where Upper Confidence Interval is still less then 5% for a p-value of 0.05
which is within acceptable limits.
Discussion
Earlier in Q-probes quality monitoring experience, it has been recognized that quality is
not a static phenomena. 10 Our study describes an approach to quality improvement for
replicate sample analysis, that permits a continuous process monitoring and performance
improvement. The QC procedures adopted from those performed in centralized
laboratory testing (e.g. imprecision, linearity and interpreter variability) as in our lab still
needs further evaluation to improve quality control. Continuous quality improvement
requires e.ffective data management. 11 We have used the statistical procedures
recommended by the National committee for clinical laboratory standards (NCCLS) EP9A. 12 Moreover the formula for calculating the percent difference is by dividing the
difference between the two results by their average as follows: (Where the "x" is the
previous day result, "y" is rerun result while13. In our study the results are accepted or
rejected on the basis of recommendations defined by American Medical Association and
as such includes tests classified as moderately complex under the Clinical Laboratory
Improvement Amendments of 1988 (CLIA' 88). Testing personnel quality control,
proficiency testing and other operation facets must conform to accreditations regulations
and rules applicable under local state laws l4 that unfortunately do not exist in our part of
the world. The fact that the strict performance improvement program of CAP (college of
American Pathologist) for routine chemistry analytes is required independently form
other laboratory tests emphasizes the importance of routine chemistry results in critical
care patients, as erroneous chemistry reports would not only lead to incorrect clinical
diagnosis but also would affect management of critical care patients. Biological
availability of the concentration of different analytes were evaluated at a conference on
analytical goals held in Aspen, Colorado, in 1976. For the analytes included in our study,
CLIA 1988 guidelines recommended that analytical goals should be at least as stringent
as the current performance of laboratories. That is why the samples rejected in our
replicate study were showing more percent variation than the acceptable range while the
samples accepted in our study were within the recommended range of percent variation.
While doing this study, we accounted for the inherent variability and the substance
interference during the analysis of parameters. In addition to routine chemistry and other
enzyme assays, proficiency testing provided by CAP surveys, a model of blind QC
(quality control) as part of Extensive External Quality control Program has also been
instituted in our laboratory for diagnostic standardization of clinical chemistry. Reexamination of randomly selected samples by different technologists and by instruments
is periodically performed. The timely maintenance of equipments, proper training of
staff, regular quality assurance meeting with technical staff and the strict vigilance are the
key reasons of these good results in our laboratory.

Recommendations
A follow up study of similar nature with statistical analysis is required to improve above
hypothesis. This exercise should be an integral part of Internal Quality Assurance
programs all labs on continuous basis. A broad base lab data should be maintained with
an effective External Quality Assurance Program on National basis.
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